This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.
Principal Investigator
Anne-Marie Langevin
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Anne-Marie Langevin
(210) 567-7460
langevin@uthscsa.edu
Arm | Description | Intervention |
---|---|---|
Treatment (ulixertinib) | Patients receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. | Given PO Other names:
Ancillary studies Other names:
|